Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma (Mino)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY Downstate Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult asthmatics
- History of or current use of oral steroids to control symptoms
Exclusion Criteria:
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Minocycline
Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
|
addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
Other Names:
|
|
Placebo Comparator: Placebos
Addition of placebo capsules po twice daily to current asthma treatment regimen
|
Addition of oral placebo capsule in addition to standard of care regimen
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decrease in oral steroid therapy requirements.
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
improvement in symptoms scores
Time Frame: 8 weeks
|
Asthma Quality of Lifes Scores (AQLQ)
|
8 weeks
|
|
improvement in spriometric parameters
Time Frame: 8 weeks
|
improvement in spirometric parameters including FEV1, FVC, FEV1/FVC, FEF25-75
|
8 weeks
|
|
improvement in morning and evening peak flow
Time Frame: 8 weeks
|
8 weeks
|
|
|
decrease in rescue inhaler usage
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Heikki31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.